English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Aims  To evaluate the safety and efficacy of once‐weekly dulaglutide 1.5 mg, a long‐acting glucagon‐like peptide‐1 receptor agonist, compared with placebo in patients with type 2 diabetes ( T2D ) on glimepiride monotherapy.    Methods  This phase  III , randomized (4 : 1; dulaglutide:placebo), double‐blind, placebo‐controlled, 24‐week study compared the safety and efficacy of once‐weekly dulaglutide 1.5 mg with placebo in sulphonylurea‐treated (≥half‐maximal dose, stable ≥3 months) patients ( N  = 300) with  T2D  and inadequate glycaemic control [glycated haemoglobin ( HbA1c ) ≥7.5 and ≤9.5% (≥58 mmol/mol and ≤80 mmol/mol)]. Analysis was carried out according to intention‐to‐treat.    Results  At baseline, the mean participant age was 58 years; mean  HbA1c  was 8.4% (68 mmol/mol) and mean weight was 85.5 kg. Dulaglutide 1.5 mg was superior to placebo at 24 weeks for  HbA1c  reduction from baseline with a between‐group  HbA1c  difference of −1.3% [95% confidence interval ( CI ) −1.6, −1.0] or ‐14 mmol/mol (95%  CI  −17, −11); p < 0.001. A greater proportion of participants in the dulaglutide group reached an  HbA1c  level of <7.0% (53 mmol/mol) compared with placebo (55.3% vs 18.9%; p < 0.001). Dulaglutide significantly decreased fasting serum glucose from baseline compared with placebo (between‐group difference −1.86 mmol/l (95%  CI  −2.58, −1.14) or −33.54 mg/dl (95%  CI  −46.55, −20.53); p < 0.001. Weight was decreased significantly from baseline in the dulaglutide group (p < 0.001); the between‐group difference was not significant. The most common treatment‐emergent adverse events for dulaglutide 1.5 mg were gastrointestinal: nausea (10.5%), diarrhoea (8.4%) and eructation (5.9%). Total hypoglycaemia was higher with dulaglutide 1.5 mg vs placebo (2.37 and 0.07 events/participant/year, respectively; p = 0.025). No severe hypoglycaemia was reported.    Conclusions  Once‐weekly dulaglutide 1.5 mg had a favourable benefit/risk profile when added to glimepiride monotherapy.

A 24‐week study to evaluate the efficacy and safety of once‐weekly dulaglutide added on to glimepiride in type 2 diabetes ( AWARD ‐8)